Sort   by:  
 Page size 
UnknownPhase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
Not available
S-EPMC5791841 | biostudies-literature
UnknownRandomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Not available
S-EPMC5569683 | biostudies-literature
UnknownRandomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
Not available
S-EPMC5569691 | biostudies-literature
UnknownNivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Not available
S-EPMC4806782 | biostudies-literature
UnknownCabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Not available
S-EPMC6804840 | biostudies-literature
UnknownQuality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
Not available
S-EPMC6804841 | biostudies-literature
UnknownPhase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
Not available
S-EPMC5569681 | biostudies-literature
UnknownTivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Not available
S-EPMC5569677 | biostudies-literature
UnknownRandomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Not available
S-EPMC6018511 | biostudies-literature
UnknownPatient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Not available
S-EPMC9479564 | biostudies-literature
Sort   by:  
 Page size